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Abstract
Background: Currently, there are no drugs for the specific treatment of hypertensive 
retinal changes. The main therapy is for the treatment of a systemic disease -  hyper­
tensive disease. Therefore, the search for ways of specific pharmacological correc­
tion of hypertensive retinal changes is of great interest. The aim of the study: To 
evaluate the correction possibility of retinal injuries with Semax in a rat model of 
hypertensive neuroretinopathy. Materials and methods: The model was performed 
by injection of N-nitro-L-arginine methyl ester (L-NAME) at a dose of 1.25 mg/100 
g of rat mass within 28 days and a single increase in intraocular pressure (IOP) to 
110 mmHg for 5 min. The retinoprotective effect of Semax at a dose of 7.2 pg/100 g 
of rat mass, in comparison with Picamilon at a dose of 3 mg/100 g of rat mass, was 
estimated by laser Doppler flowmetry (LDF) and electroretinography (ERG). Re­
sults: The use of Semax led to an increase in retinal perfusion by 62.7%, p < 0.05, in 
comparison with the group with the model, and by 9.9%, p < 0.05, in comparison 
with Picamilon; an increase in the b/a coefficient by 31.4% in comparison with the 
group with the model, p < 0.05, and by 14.6%, p < 0.05 in comparison with Picami­
lon. Conclusion: The neuroretinoprotective effect of Semax in correction of hyper­
tensive retinal changes in rats may be due to the presence of neuroprotective, neu- 
rometabolic, antioxidant and endothelioprotective effects in Semax. Thus, Semax can 
be a promising agent in hypertensive neuroretinopathy treatment.
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Introduction. With long-term, ad­
vanced hypertensive disease, the target organs 
(retina, kidneys, brain) are affected. Hyper­
tension can affect the eyes in several ways, 
including the development of retinopathy and 
optic neuropathy. Hypertension is a risk factor 
for other eye diseases, including occlusion of 
the central retinal artery (CRA) and its 
branches, macroaneurysms of the retinal arter­
ies and others [1, 2].
Published data indicate a 3-14% preva­
lence of hypertensive retinopathy in patients 
over 40 years of age. The pathogenetic link of 
hypertensive retinopathy is retinal ischemia, 
which can lead to the optic nerve atrophy [3, 
4, 5]. In 63 % of patients with hypertension, 
there are manifestations of hypertensive angi­
opathy. Vascular endothelium is attributed to 
the most early damaged target organ in hyper­
tension, as well as to the cause of increased 
blood pressure [6, 7].
Special interest is paid to the develop­
ment of short-chain peptide drugs for the cy- 
toprotection [8, 9, 10, 11, 12], in particular, 
neuroprotection [13, 14]. One of the actively 
studied classes of peptide regulators are mel- 
anocortins, which accelerate regeneration in 
the neuromuscular system, have a protective 
effect on damage to the central nervous sys­
tem. Melanocortins have hormonal activity, 
positive effect on the development of the 
nervous system, etc. This class of peptides 
includes an analog of adrenocorticotropic 
hormone (ACTH)(4 -1 0 ) with prolonged action 
Semax. To date, Semax is the only widely 
used in clinic neurotropic drug developed on 
the basis of melanocortins. Semax has no 
hormonal activity and retains a significant 
part of the spectrum of neurotropic effects of 
natural melanocortins. The heptapeptide Se­
max is a synthetic analogue of ACTH(4-10) 
which exerts marked nootropic and neuropro- 
tective activities [15], protects effectively the 
brain against ischemic stroke [14]. Semax 
promotes the survival of neurons during glu­
tamate excitotoxicity [16], protects against the
optic nerve atrophy and optic neuritis of in­
flammatory or toxic-allergic etiology [17].
At present, the spectrum of physiologi­
cal and pharmacological activity of Semax is 
actively being studied, because many aspects 
of the therapeutic effects of this drug remain 
unknown. Based on literature data, tripeptide 
Pro-Gly-Pro (PGP) was predominant in a 
mixture of Semax derivatives in rat blood 
plasma and brain tissues just 1 h after intra- 
peritoneal administration of Semax [18]. In­
dependent effects of PGP were revealed re­
cently, including an effect on cell culture sur­
vival in oxidative stress [19]. The effect of 
Semax and PGP previously was shown on the 
expression of genes that encode neurotrophic 
factors and their receptors in a model of brain 
ischemia in rats [20]. However, despite the 
advances described above, the molecular 
mechanisms underlying the Semax neuropro- 
tective action and the degree of PGP partici­
pation in them remain obscure [15].
In cerebral ischemia, Semax showed 
neuroprotective, neurometabolic and antioxi­
dant effects, and also promotes the synthesis 
of BDNF and NGF in the brain [13]. It was 
shown that Semax and PGP increased prolif­
eration of the neuroglia, endothelium, and 
progenitor cells in the subventricular zone. 
Semax influences the genes expression asso­
ciated with the vasodilation of arteries. It was 
shown that capillary bore dilation was ob­
served as early as 15 min after the administra­
tion of Semax [20].
Under transient middle cerebral artery 
occlusion (tMCAO) conditions, it was found 
that Semax initiated mRNA expression that 
counteracted ischaemia-reperfusion (IR). In 
particular, Semax suppressed inflammatory 
and activated neurotransmitter genes, whereas 
the genetic response initiated by IR activates 
inflammatory and suppresses neurotransmitter 
genes. It was revealed that significant com­
pensation effects of Semax peptide on in­
flammatory and neurotransmitter genetic re­
sponses after tMCAO, which may account for
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the neuroprotective action of Semax under IR 
conditions. Thus, an important feature of Se- 
max is the normalization of mRNA expres­
sion patterns that are disturbed during is- 
chaemia [21].
An important feature of Semax is the 
speed of the onset of the therapeutic effect, 
the absence of drug dependence and with­
drawal syndrome. After intranasal administra­
tion, Semax penetrates the blood-brain barrier 
within a few minutes, and with a single ad­
ministration, the therapeutic effect lasts up to 
24 hours. The prolonged action of Semax is 
due to its sequential transformation, while 
most of the properties of the drug are pre­
served in its fragments EHFPGP and HFPGP. 
These fragments are quite stable and inde­
pendently modulate cholinergic neurotrans­
mission and nitric oxide synthesis [13].
Intranasal administration of Semax over 
the 7-day treatment course resulted in a 25% 
decrease of infarct volume in the prefrontal 
cortex and cognitive function recovery over 
the long term [22]. Recently, it was shown 
that Semax activates and induces PGC-1a in 
the penumbral neurons in a model of focal 
ischemia and exert neuroprotective effects 
through these mechanisms. The target mole­
cule -  the PGC-1a transcriptional coactivator 
is known for its pleiotropic potentiating effect 
on neuron viability and functionality. This 
study was performed in a model of photo­
chemically induced thrombosis of prefrontal 
cortex blood vessels, mimicking the patho­
genesis of acute ischemic stroke. Indeed, on 
the third day after photochemical-induced 
thrombosis, signs of degenerative changes in 
the microcirculatory bed were detected, such 
as multiple hemorrhages, pronounced vasodi­
lation, and erythrocyte stasis. Secondary post­
stroke perfusion disturbances led to a signifi­
cant progression of the penumbra, while the 
administration of Semax limited the disturb­
ances of peri-infarction microcirculation ob­
served after photochemical-induced throm­
bosis [23].
The intramuscular injection of Semax at 
a dose of 200 pg/kg for 10 days in animals 
with diabetes did not significantly influence 
the content of circulating endothelial cells and
stable metabolites of NO, but the concentra­
tion of von Willebrand factor and endothelin- 
1 was significantly reduced (by 16.8 and 
15.4%, respectively, p < 0.01) as compared to 
the control [24].
In addition, it was shown that the ad­
ministration of Semax had antioxidant action 
and caused the increase in the antioxidant en­
zymes activity in a model of diabetes melli- 
tus. Under the influence of Semax, the content 
of ceruloplasmin was lower. The administra­
tion of Semax and Sulodexid had antioxidant 
action, similar to Semax injection only. The 
decrease in the content of malondialdehyde 
was 17.8% (p < 0.01), and acylhydroperox- 
ides -  by 28.4% (p < 0.01). The drug had a 
stimulating action on the activity of superox­
ide dismutase (SOD) (by 32.7% compared to 
the control, p < 0.01) and catalase -  by 23.6% 
(p > 0.05). The received results show the an­
tioxidant action of Semax in diabetes mellitus 
and confirm the prospect of their use in the 
endothelial dysfunction correction as a sepa­
rate drug or in the combination with some 
other endothelioprotectors [25].
Studying the new perspective ways of 
neuroprotection in retinal injuries, in particu­
lar, developing in hypertension, is of great 
interest [26]. Therefore, an important task is 
to find specific and effective agents for treat­
ment of hypertensive neuroretinopathy. To 
study the new pharmacological properties of 
drugs, it is necessary to conduct further stud­
ies in vivo [27, 28, 29, 30] on the adequate 
experimental pathology models [31].
Thus, it is perspective to study the pos­
sibility of pharmacological correction of hy­
pertensive retinal changes with Semax in la­
boratory rats.
The aim of this research is to evaluate 
the correction possibility of retinal injuries 
with Semax in a rat model of hypertensive 
neuroretinopathy.
Materials and Methods
Animals. The experiments were con­
ducted on 40 Wistar rats of average weight 
250 g. For the study, the healthy animals were 
taken, having passed the quarantine. Ethical 
principles of conducting experiments on la­
boratory rats were observed in accordance
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with the European Convention for the Protec­
tion of Vertebrate Animals Used for Experi­
mental and Other Scientific Purposes, CETS 
No. 123. Manipulations on animals were per­
formed under general anaesthesia with intra- 
peritoneal (i.p.) administration of chloral hy­
drate solution at a dose of 30 mg/100 g of rat 
mass.
Design o f the Experiment. The experi­
ment included the following groups:
1) a control (with i.p. saline for 28 days) 
(n = 10);
2) a group with simulated hypertensive 
neuroretinopathy (HNRP) (n = 10);
3) a group with Semax at a dose of 7.2 
Mg/100 g in the model of HNRP (n = 10);
4) a group with Picamilon at a dose of 3 
mg/100 g in the model of HNRP (n = 10).
HNRP simulation was conducted by 
daily i.p. administration of N-nitro-L-arginine 
methyl ester (L-NAME) (Sigma, Germany) at 
a dose of 1.25 mg/100 g of rat mass in a solu­
tion form within 28 days and a single increase 
in intraocular pressure (IOP) to 110 mmHg by 
applying mechanical pressure to the anterior 
chamber of the eye for 5 min on the 26th day 
of the experiment [26]. The increase in IOP 
was conducted under general anaesthesia (i.p. 
chloral hydrate, 30 mg/100 g of rat mass).
For the study, Semax nasal drops, 0.1% 
(PEPTOGEN Innovative Research and Pro­
duction Center) were used. In diseases of the 
optic nerve, Semax is instilled 2-3 drops in 
each nasal passage 2-3 times/day. The daily 
dose is 600-900 Mg. The course of treatment is 
7-10 days [32]. 1 drop of the standard solution 
contains 50 Mg of the active substance, 0.05 
ml of the solution. The conversion factor for 
an adult with a body weight of 70 kg is 39. 
For a rat weighing 250 g, the conversion fac­
tor is 7.0. Thus, the estimated dose (ED) of 
Semax was calculated:
EDvol = 0.9 • 39 / 70 • 7 = 0,072 
(ml/kg/day)
EDm = 0.072 • 50 / 0.05 = 72 
(M-g/kg/day) = 7.2 (Mg/100 g/day)
A solution of nasal drops was adminis­
trated into the nasal cavity using a micropi­
pette once a day daily for 7 days, from the 
22nd to the 28th days of the experiment.
The administration of Picamilon (a ref­
erence drug) at a dose of 3 mg/100 g 
(Pharmstandard-UfaVITA JSC, Russia) was 
conducted 60 minutes before L-NAME ad­
ministration, from the 22nd to the 28th days of 
the experiment, inclusive. Picamilon was dai­
ly administered intragastrically (i.g.). The 
choice of Picamilon as a reference drug in the 
hypertensive neuroretinopathy model, the 
dose and route of its administration to rats is 
based on its effectiveness in previously con­
ducted experimental studies at the Research 
Institute of Pharmacology of Living Systems 
(BelSU) and published data [26].
The effectiveness of the pharmacologi­
cal correction with Semax and Picamilon was 
evaluated on the 29th day of the experiment by 
the b/a coefficient and retinal microcirculation 
level.
Laser Doppler Flowmetry. 72 hours af­
ter the increase in IOP, the retinal perfusion in 
rats was measured by LDF. LDF is a non- 
invasive method for assessing the blood flow 
in tissues. In LDF, a coherent laser beam il­
luminates the vascular tissue and measures 
the Doppler shift caused by the movement of 
red blood cells. The movement of red blood 
cells causes a shift in the frequency of scat­
tered light, and the walls of the vessels pro­
duce static scattering without any shift in the 
frequency of light and serve as a reference 
signal. The registration was performed using 
MP150 production Biopac System, Inc. (Go- 
leta, USA), a computer-based data acquisition 
system with the AcqKnowledge 4.2 software, 
and a TSD-144 needle-type sensor (Biopac 
System, Inc., Goleta, USA). After the rats 
were anaesthetized, the retinal perfusion was 
measured at 10 points on the circumference of 
the eye [4].
Electroretinography. ERG is the elec­
trical response of the retina to light stimula­
tion. A flash of light causes a two-phase nega­
tive-positive waveform. Wave a, which oc­
curs at the photoreceptor level, is the initial 
large negative wave. The b wave that occurs
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in the inner retina is the next big positive 
component. The effects of drug therapy can 
be detected and quantified using ERG [33]. 
The assessment of retinal functional activity 
was conducted with a- and b-wave ampli­
tudes. ERG was performed in rats with our 
previously published method [2, 4]. The ratio 
of the amplitudes of the b- and a-waves, the 
b/a coefficient, was calculated.
Statistical Data Processing. The data 
were checked for type of distribution. In nor­
mal distribution, the average value (M) and 
standard error of the mean (m) were calculat­
ed. In abnormal distribution, the median (Me) 
and the quartile range (QR) were calculated. 
Between-group differences were analyzed by 
parametric (t-Student criterion) or non- 
parametric (Mann-Whitney U-test) methods. 
The differences were determined at a 0.05 
significance level. The statistical analyses 
were performed using Statistica 10.0 soft­
ware.
Results.
LDF results. Results of retinal microcir­
culation evaluation are presented in Figure 1. 
In the group with the HNRP simulation, the 
retinal perfusion decreased by 44.3% 
(p < 0.05) in comparison with the control. 
When correcting HNRP with Semax at a dose 
of 7.2 |ig/100 g, perfusion level differed sig­
nificantly (by 9.4%, p < 0.05) from the mean 
value of the control group, increased by 
62.7% (p < 0.05) in comparison with the 
group with HNRP and differed significantly 
(by 9.9%, p < 0.05) from the mean of the 
group with Picamilon at a dose of 3 mg/100 g.
When correcting HNRP with Picamilon, 
the microcirculation level in the retina dif­
fered significantly (by 17.6%, p < 0.05) from 
the mean of the control group, increased by 
48.0% (p < 0.05) in comparison with the 
group with HNRP simulation.
HNRP -  hypertensive neuroretinopathy; * p < 0.05 compared to the control; 
у p < 0.05 compared to the group with simulated hypertensive neuroretinopathy; 
x p < 0.05 compared to the group with Picamilon 
Fig. 1. Retinal microcirculation level in experimental groups
Results o f the ERG, and b/a Counting. groups is presented in Table 1. Further, the
The influence of Semax and Picamilon on the b/a coefficient was calculated, the values of
values of amplitudes of a- and b-waves in which are presented in Table 2. In the group
Оригинальная статья
Original article
Научные результаты биомедицинских исследований. 2021;7(3):272-280 
Research Results in Biomedicine. 2021:7(3):272-280
with HNRP simulation, the b/a coefficient de­
creased by 26.8% in comparison with the con­
trol group (p < 0.05). Against the background 
of Semax, the b/a coefficient increased by 
31.4% in comparison with the group with no 
treatment (p < 0.05), and by 14.6% in com­
parison with the group with Picamilon 
(p < 0.05). In the group with Picamilon, the 
b/a coefficient did not reach the target values, 
but increased by 14.7% in comparison with 
the group with no treatment (p < 0.05).
Table 1
Influence of Semax and Picamilon on the a- and b- wave amplitudes when correcting
: ±
Experimental Groups The a-Wave Amplitude (n = 10)
The b-Wave Amplitude 
(n = 10)
Control 0.36 ± 0.03 0.94 ± 0.07
HNRP 0.34 ± 0.02 0.65 ± 0.05 *
HNRP+Semax, 7.2 Mg/100 g 0.35 ± 0.03 0.88 ± 0.07 у
HNRP+Picamilon, 3 mg/100 g 0.36 ± 0.04 0.79 ± 0.06 *у
Note: HNRP -  hypertensive neuroretinopathy; * p < 0.05 compared to the control; у p < 0.05 compared to the group 
with simulated HNRP; x p < 0.05 compared to the group with Picamilon.
Table 2
Influence of Semax and Picamilon on the value of the b/a coefficient when correcting 
________experimental hypertensive neuroretinopathy (M ± m; n = 10), R.U.________
Experimental Groups b/a (n = 10)
Control 2.61 ± 0.08
HNRP 1.91 ± 0.06 *
HNRP+Semax, 7.2 Mg/100 g 2.51 ± 0.12 ^
HNRP+Picamilon, 3 mg/100 g 2.19 ± 0.11*у
Note: R.U. -  relative units; HNRP -  hypertensive neuroretinopathy; * p < 0.05 compared to the control; у p < 0.05 
compared to the group with simulated HNRP; x p < 0.05 compared to the group with Picamilon.
In our opinion, the protective effect of 
Semax in correction of hypertensive retinal 
changes in rats may be associated with the 
presence of neuroprotective, neurometabolic 
antioxidant and endothelioprotective effects in 
Semax. Based on the obtained data of the ret­
inal perfusion in the animal groups in the 
model of hypertensive neuroretinopathy, it 
follows that a positive effect on the state of 
the retinal perfusion in descending order has 
Semax at a dose of 7.2 Mg/100 g, then Picami­
lon at a dose of 3 mg/100 g. Based on the ob­
tained values of the b/a coefficient, it follows 
that a positive effect on the electrophysiologi- 
cal state of the retina in the correction of hy­
pertensive neuroretinopathy in descending 
order has Semax at a dose of 7.2 Mg/100 g, 
then Picamilon at a dose of 3 mg/100 g.
It is well known, that the key link in the 
pathogenesis of endothelial dysfunction is NO 
deficiency, and the use of drugs that increase 
NO production has an endothelioprotective 
effect. Oxidative stress in the retina, which
occurs in hypertensive neuroretinopathy, 
leads to a decrease in NO production, acceler­
ation of its breakdown, and suppression of the 
expression of endothelial NO synthase 
(eNOS) [34]. The reasons for the decrease in 
bioavailability of NO under oxidative stress 
are an increased level of dimethylarginine 
formation, which is an endogenous competi­
tive inhibitor of eNOS, as well as a violation 
of the penetration of L-arginine into endothe­
lial cells under the influence of oxidized low- 
density lipoproteins [35]. In connection with 
the above, the study of the retinoprotective 
effect of Semax as a potential corrector of en­
dothelial dysfunction is of particular interest 
in the model of hypertensive neuroretinopa­
thy.
It is planned to study endothelioprotec- 
tive effect of Semax at a dose of 7.2 Mg/100 g 
of rat mass in the retinal vessels in correction 
of hypertensive retinal changes in rats using 
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Conclusion. Thus, when correcting 
HNRP with Semax at a dose of 7.2 |ig/100 g, 
retinal perfusion increased by 62.7% (p <
0.05) in comparison with the group with no 
correction and differed significantly (by 9.9%, 
p < 0.05) from the mean value of the group 
with Picamilon at a dose of 3 mg/100 g.
In the group with Semax, the b/a coeffi­
cient increased by 31.4% in comparison with 
the group with no correction (p < 0.05), and 
by 14.6% in comparison with the group with 
Picamilon (p < 0.05). Therefore, Semax can 
be a promising agent in the treatment of hy­
pertensive neuroretinopathy.
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